Covance is expanding its global bioanalytical footprint and adding scientific leaders to its biologics team. It is expanding its large-molecule bioanalytical space co-located with its central laboratory facility in Indianapolis.

The expansion, anticipated to open during the second half of 2014, is doubling the company's large-molecule capacity and is expected to add approximately 100 new positions over the next five years.

As part of the ongoing investment in biologics, the company appointed Mike Holsapple, Ph.D., as Covance's executive director of global immunotoxicology. Holsapple is a fellow in the Academy of Toxicological Sciences (ATS) and past president of the Society of Toxicology.

Covance also has launched molecule management teams of experienced scientific leaders who work closely with clients to develop and implement tailored solutions for the development of their biologics, which will leverage Covance's broad portfolio of services, including discovery, preclinical, early and late clinical, central laboratories and commercialization.